Core Viewpoint - Innotech's stock price has shown significant volatility, with a recent decline of 2.00% and a total market capitalization of 5.027 billion yuan, despite a year-to-date increase of 21.60% [1] Group 1: Stock Performance - As of January 13, Innotech's stock price is 36.70 yuan per share, with a trading volume of 113 million yuan and a turnover rate of 4.36% [1] - The stock has increased by 18.81% over the last five trading days, 17.93% over the last 20 days, and 22.01% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, a year-on-year decrease of 36.56%, and a net profit attributable to shareholders of 131 million yuan, down 46.37% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, Innotech has 8,037 shareholders, an increase of 10.57% from the previous period, with an average of 8,627 circulating shares per shareholder, a decrease of 8.86% [2] - The company has distributed a total of 152 million yuan in dividends since its A-share listing [3] - The medical device ETF (159883) is among the top ten circulating shareholders, holding 498,000 shares as a new shareholder [3] Group 4: Company Overview - Innotech, established on February 6, 2006, and listed on July 28, 2022, specializes in the research, production, and sales of POCT rapid diagnostic products [1] - The company's main revenue sources include respiratory series (96.49%), other reagent series (2.99%), and preconception care series (0.51%) [1] - Innotech operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics [1]

Market Overview - The Shanghai Composite Index closed at 4165.29 points, above the annual line, with a change of 1.09% [1] - The total trading volume of A-shares reached 36,446.14 billion yuan [1] Stocks Breaking Annual Line - A total of 241 A-shares have broken above the annual line, with notable stocks including: - Innotech (乖离率 16.78%) - Landun Optoelectronics (乖离率 15.57%) - Tonghui Information (乖离率 14.78%) [1][2] - Other stocks with smaller deviations just above the annual line include: - Jingwei Huirong - Longhua New Materials - Metro Design [1] Individual Stock Performance - Innotech (688253): Today's change of 16.92%, turnover rate of 16.87%, latest price at 37.45 yuan, deviation rate of 16.78% [2] - Landun Optoelectronics (300862): Today's change of 16.12%, turnover rate of 30.39%, latest price at 29.54 yuan, deviation rate of 15.57% [2] - Tonghui Information (920090): Today's change of 29.97%, turnover rate of 39.83%, latest price at 8.63 yuan, deviation rate of 14.78% [2] ETF Performance - Food and Beverage ETF (515170): Recent five-day change of 0.89%, PE ratio of 20.39, latest shares at 10.21 billion, net subscription of 10.01 million yuan [4] - Gaming ETF (159869): Recent five-day change of 9.79%, PE ratio of 40.89, latest shares at 9.30 billion, net subscription of 140 million yuan [4] - Sci-Tech 50 ETF (588000): Recent five-day change of 7.77%, PE ratio of 178.22, latest shares at 53.49 billion, net subscription of 310 million yuan [4] - Cloud Computing 50 ETF (516630): Recent five-day change of 15.13%, PE ratio of 100.52, latest shares at 2.80 billion, net subscription of 4.04 million yuan [4]

Market Overview - The market showed strong fluctuations throughout the day, with all three major indices rising over 1%, and the Shanghai Composite Index achieving a 17-day consecutive rise [1] - AI application sectors experienced a significant surge, with stocks like BlueFocus and Hand Information hitting the daily limit [1] - The commercial aerospace concept continued its strong performance, with China Satellite and China Satcom both reaching new highs [1] - The brain-computer interface concept was also active, with stocks like DaoTech and Yanshan Technology hitting the daily limit [1] - Over 4,100 stocks in the Shanghai, Shenzhen, and Beijing markets rose, with a total transaction volume of 3.64 trillion, setting a new record for daily trading in A-shares [1] AI Marketing - The AI marketing concept saw a wave of limit-up stocks, including Gravity Media, Leo Holdings, and BoRui Communication [4] - Elon Musk announced on social media that he would open-source the latest content recommendation algorithm for the X platform within a week, interpreted by the market as his entry into the GEO space [4] - DeepSeek is set to release its next-generation flagship AI model, DeepSeek V4, in February, which reportedly outperforms major models like Anthropic Claude and OpenAI GPT series in programming capabilities [4][7] - Anthropic's Claude Code received a significant update, marking a new phase in global AI programming competition [4] Aerospace Sector - The aerospace sector continued to rise, with stocks like Luxin Investment, Goldwind Technology, and Daye Shares hitting the daily limit [10] - China applied for frequency resources for over 200,000 satellites, indicating a strategic national-level initiative [11] - Experts believe that the establishment of the Radio Innovation Institute will accelerate the 6G process, integrating satellite networks with ground communication networks [14] AI Medical - The AI medical sector also performed well, with companies like Meinian Health and Dean Diagnostics seeing consecutive gains [15] - OpenAI launched "ChatGPT Health," a health-related dialogue space that connects electronic medical records and health applications [15] - The demand for AI in healthcare is expected to grow significantly, driven by an aging population and an increase in chronic disease patients [18]

Market Overview - The Shanghai Composite Index is at 4128.91 points, above the annual line, with a change of 0.21% [1] - The total trading volume of A-shares is 17287.95 billion yuan [1] Stocks Above Annual Line - A total of 122 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - 蓝盾光电 (Blue Shield Optoelectronics) at 16.31% - 英诺特 (Innotech) at 13.71% - 立方控股 (Cube Holdings) at 12.65% [1] Detailed Stock Performance - The top three stocks with the highest daily increase and their respective metrics are: - 蓝盾光电: Daily increase of 16.86%, turnover rate of 16.56%, latest price at 29.73 yuan [1] - 英诺特: Daily increase of 13.83%, turnover rate of 10.21%, latest price at 36.46 yuan [1] - 立方控股: Daily increase of 14.32%, turnover rate of 10.20%, latest price at 31.61 yuan [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - 中化装备 (Sinochem Equipment) with a daily increase of 9.98% and a deviation rate of 8.83% [1] - 中国长城 (China Great Wall) with a daily increase of 9.99% and a deviation rate of 8.10% [1] - 中国科传 (China Science Communication) with a daily increase of 7.22% and a deviation rate of 7.03% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the annual line with smaller deviation rates include: - 熊猫乳品 (Panda Dairy) with a deviation rate just above the annual line [1] - 润普食品 (Runpu Food) with a similar status [1] - 顶点软件 (Vertex Software) also recently crossed the annual line [1]

Group 1 - The core viewpoint of the article highlights the strong performance of AI healthcare and pharmaceutical concepts in the early trading session, with specific companies like Dean Diagnostics and Meien Health achieving consecutive gains [1] - Companies such as Ruizhi Medicine, Innotech, Hongbo Medicine, and Weining Health also experienced upward movement in their stock prices, indicating a broader trend in the sector [1]

Group 1 - The company has recently obtained two new product qualifications, enhancing its capabilities in detecting low-abundance biomarkers, particularly for neurodegenerative diseases like Alzheimer's [1] - The approved products utilize single-molecule array detection technology, significantly improving sensitivity compared to traditional immunoassays, with a detection limit at the fg level (1 fg = 10^-12 mg) [1] - The ability to simultaneously detect multiple biomarkers represents a technological leap from traditional immunoassays to single-molecule precision detection, providing critical support for ultra-early diagnosis of diseases [1] Group 2 - The acquisition of these qualifications broadens the company's product range and enhances its market expansion capabilities and core competitiveness [2]

上述获批产品依托于单分子阵列检测技术，为破解低丰度生物标志物检测难 题提供超灵敏工具。以阿尔茨海默病为代表的神经系统疾病，在人口加速老龄化 的背景下，已成为患者基数大、早期诊断难度大的常见病，其相关生物标志物因 血脑屏障的存在，在血液中的含量极低。公司获批产品检测灵敏度较传统免疫检 测大大提升，检测下限为 fg 级别（1fg=10 -12mg），并可同时检测多种生物标志物， 达成从传统免疫检测向单分子精准检测的跨越，为疾病超早期诊断提供关键技术 支撑。 二、对公司的影响 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 证券代码：688253 证券简称：英诺特 公告编号：2026-001 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）近期新取得产品资 质 2 项，具体情况如下表所示： | 序号 | 获批主体 | 产品名称 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The semiconductor sector experienced significant gains, with companies like Zhongwei rising over 14%, Yandong Micro over 12%, and Shanghai Xinyang over 11% [1] - The semiconductor industry is benefiting from multiple favorable catalysts, including increased government support for domestic chip development and a substantial rise in the shareholding of the National Integrated Circuit Industry Investment Fund in SMIC from 4.79% to 9.25% [3] - TrendForce has revised its price expectations for memory chips, forecasting a 55-60% increase in DRAM and a 33-38% increase in NAND contract prices for Q1, which is significantly higher than previous predictions [3] Group 2 - CITIC Construction Investment reports that the semiconductor equipment sector is entering a growth cycle, with equipment orders expected to maintain high growth rates [4] - The Taikang Semiconductor Quantitative Stock Fund has achieved over 100% returns since its inception in May 2024, with a 1.28% increase in net value on the previous day [5] - Zhejiang Securities anticipates that the semiconductor equipment index will significantly outperform the market in 2025, with current valuations at the 28th percentile, indicating strong growth in front-end equipment revenue and explosive growth in back-end equipment [5]

Core Viewpoint - As of December 24, a total of 136 stocks in the Shanghai and Shenzhen markets have experienced net buying through financing for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Notable Financing Net Inflows - The stock with the longest consecutive net buying days is Innotek, which has seen net buying for 12 consecutive trading days [1] - Other stocks with significant consecutive net buying days include China Mobile, New Ray Energy, Industrial Fulian, High德 Infrared, Stellar Technology, Lakala, Bomin Electronics, and YK Medical [1]